search
Back to results

A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
insulin icodec
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Chinese male or female
  • Aged 18-64 years (both inclusive) at the time of signing informed consent
  • Body mass index between 18 and 38 kg/m^2 (both inclusive)
  • HbA1c (glycated haemoglobin) below or equal to 9% at screening
  • Current daily basal insulin treatment greater than or equal to 0.2 (I)U/kg/day greater than or equal to 60 days prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses greater than or equal to 60 days prior to the day of screening:
  • Any metformin formulation
  • Other oral antidiabetic drugs: DPP-4 (Dipeptidyl-peptidase-4) Inhibitors , SGLT2 (Sodium-glucose co-transporter-2) inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs)
  • Oral or injectable GLP-1 (Glucagon Like Peptide 1) Receptor Agonists

Exclusion Criteria:

  • Known or suspected hypersensitivity to trial product(s) or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice).
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and run-in. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening

Sites / Locations

  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Insulin icodec

Arm Description

The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks

Outcomes

Primary Outcome Measures

Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state
pmol*h/L

Secondary Outcome Measures

Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state divided by dose
(pmol*h/L)/(U/kg)
Maximum observed serum insulin icodec concentration after the last dose
pmol/L
Maximum observed serum insulin icodec concentration after the last dose divided by dose
(pmol/L)/(U/kg)
Time to maximum observed serum insulin icodec concentration after the last dose
hours
Terminal half-life for insulin icodec at steady state
hours

Full Information

First Posted
April 22, 2021
Last Updated
May 16, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04857398
Brief Title
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes
Official Title
A Trial Investigating the Pharmacokinetic Properties of Insulin Icodec in Chinese Subjects With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
April 28, 2021 (Actual)
Primary Completion Date
April 6, 2022 (Actual)
Study Completion Date
April 6, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is looking at the way insulin icodec stays and moves over time in the blood after injections in Chinese people with type 2 diabetes. Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin of the thigh. There will also be a run-in period that will last between 1 week and 8 weeks with daily doses of insulin degludec before start on insulin icodec. The study will last for about 15 to 22 weeks. Participants will have about 17 visits with the study doctor including phone contact during your run-in period. Participants will have blood samples taken at the clinic visits. Several samples of participants blood will be taken for up to 48 hours after getting the first and the last dose of insulin icodec. Participants must be a Chinese person diagnosed with type 2 diabetes for at least 6 months and be on basal insulin treatment for at least 2 months before participating in the study. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Insulin icodec
Arm Type
Experimental
Arm Description
The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks
Intervention Type
Drug
Intervention Name(s)
insulin icodec
Intervention Description
Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin. The study will last for 15 to 22 weeks.
Primary Outcome Measure Information:
Title
Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state
Description
pmol*h/L
Time Frame
From 0 to 168 hours after trial product administration (Day 36)
Secondary Outcome Measure Information:
Title
Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state divided by dose
Description
(pmol*h/L)/(U/kg)
Time Frame
From 0 to 168 hours after trial product administration (Day 36)
Title
Maximum observed serum insulin icodec concentration after the last dose
Description
pmol/L
Time Frame
From 0 to 168 hours after trial product administration (Day 36)
Title
Maximum observed serum insulin icodec concentration after the last dose divided by dose
Description
(pmol/L)/(U/kg)
Time Frame
From 0 to 168 hours after trial product administration (Day 36)
Title
Time to maximum observed serum insulin icodec concentration after the last dose
Description
hours
Time Frame
From 0 to 168 hours after trial product administration (Day 36)
Title
Terminal half-life for insulin icodec at steady state
Description
hours
Time Frame
Terminal part of the serum insulin icodec concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after last trial product administration (Day 36)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chinese male or female Aged 18-64 years (both inclusive) at the time of signing informed consent Body mass index between 18 and 38 kg/m^2 (both inclusive) HbA1c (glycated haemoglobin) below or equal to 9% at screening Current daily basal insulin treatment greater than or equal to 0.2 (I)U/kg/day greater than or equal to 60 days prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses greater than or equal to 60 days prior to the day of screening: Any metformin formulation Other oral antidiabetic drugs: DPP-4 (Dipeptidyl-peptidase-4) Inhibitors , SGLT2 (Sodium-glucose co-transporter-2) inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs) Oral or injectable GLP-1 (Glucagon Like Peptide 1) Receptor Agonists Exclusion Criteria: Known or suspected hypersensitivity to trial product(s) or related products. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and run-in. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency (Dept.1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100853
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes

We'll reach out to this number within 24 hrs